PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions
Executive Summary
FDA is emphasizing the difficulties of industry requested meetings in its early public discussion of the 2007 Prescription Drug User Fee Act reauthorization
You may also be interested in...
EOP2A Guidance Allows That Resource Constraints Might Block Meetings
FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.
EOP2A Guidance Allows That Resource Constraints Might Block Meetings
FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.
Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key
FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.